scholarly journals Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland

Oncotarget ◽  
2019 ◽  
Vol 10 (4) ◽  
pp. 480-493
Author(s):  
Ravi Doddapaneni ◽  
Wensi Tao ◽  
Andrea Naranjo ◽  
Neda Nikpoor ◽  
David T. Tse ◽  
...  
Keyword(s):  
Growth Factor ◽  
Adenoid Cystic Carcinoma ◽  
Fibroblast Growth Factor ◽  
Lacrimal Gland ◽  
Therapeutic Target ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Adenoid Cystic

Genomic profiling by cell-free circulating tumor DNA in patients with recurrent adenoid cystic carcinoma (ACC) and the potential activity of selective fibroblast growth factor receptor (FGFR) inhibitors.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15018-e15018
Author(s):  
Cesar Augusto Perez ◽  
Giselle Dutcher ◽  
Zoukaa Sargi ◽  
Nelson Guevara ◽  
David Tse ◽  
...  
Keyword(s):  
Growth Factor ◽  
Adenoid Cystic Carcinoma ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Circulating Tumor Dna ◽  
Comprehensive Cancer Center ◽  
Fibroblast Growth ◽  
Adenoid Cystic ◽  
Tumor Dna

e15018 Background: Few effective systemic therapies are available for adenoid cystic carcinoma (ACC). Multitargeted Tyrosine Kinase inhibitors (TKIs) as Lenvatinib and Rivoceranib can provide disease control and limited radiographic response in unselected ACC patients. Next-generation sequencing in tissue (tNGS) has identified MYB gene fusions in [patients with ACC but currently, only Notch1 mutations have an available targeted agent. The fibroblast growth factor receptor (FGFR) pathway is a downstream target of MYB. Methods: We retrospectively reviewed adult patients with a diagnosis of recurrent ACC seen at the University of Miami Sylvester Comprehensive Cancer Center between January 1, 2019 and October 31, 2020. Commercially available cell free DNA panel of 73 genes was used for analyzing circulating tumor DNA (ctDNA). Patients included had radiographically measurable disease and both tNGS and ctDNA data available. Results: Twelve patients were included. Median age at diagnosis was 54 years (28 - 68), and 69% were males. 83% of the patients had genomic abnormalities reported by tNGS, with the same number by ctDNA sequencing. Seven patients (58%) had genomic abnormalities in ctDNA of potentially therapeutic significance which were not found on tNGS, including FGFR1 amplification as well as FGFR2, BRAF, KRAS and JAK2 mutations. Three patients with FGFR genomic abnormalities only seen by ctDNA had been previously treated with Lenvatinib. One patient with primary lacrimal gland ACC metastatic to the liver and tNGS positive for NOTCH 1 had disease progression despite treatment with Lenvatinib and a NOTCH γ-secretase inhibitor. The patient’s ctDNA reported a FGFR2 mutation. The patient was started on Erdafitinib, an oral selective FGFR inhibitor, achieving a partial response at the primary site and metastatic liver lesions and remained on therapy for 7 months. Follow-up ctDNA after 3 months of therapy noted resolution of both FGFR and NOTCH abnormalities. Conclusions: Patients treated with lenvantinib or other TKIs may develop acquired resistance mutations and other genomic abnormalities. ctDNA can reveal additional therapeutic targets not present on tNGS and can be repeated serially. FGFR genomic abnormalities can be a driver mutation in patients with refractory advanced ACC and the activity of Erdafinib should be evaluated in this subset of patients with few therapeutic options.

Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer

2013 ◽  
Vol 7 (8) ◽  
pp. 759-765 ◽  
Author(s):  
Liu Hong ◽  
Yu Han ◽  
Jinqiang Liu ◽  
Lubi Brain
Keyword(s):  
Gastric Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Therapeutic Target ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth

Fibroblast growth factor receptor 2: a new potential therapeutic target for human cancer

2015 ◽  
Vol 46 (2) ◽  
pp. 339-340 ◽  
Author(s):  
Chang Cheng ◽  
Wei Hu ◽  
Li-Ping Liu ◽  
Jun Li
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Therapeutic Target ◽  
Fibroblast Growth Factor Receptor ◽  
Human Cancer ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Potential Therapeutic Target

scholarly journals Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells

2012 ◽  
Vol 11 (9) ◽  
pp. 2010-2020 ◽  
Author(s):  
Yoko Matsuda ◽  
Masahito Hagio ◽  
Tomoko Seya ◽  
Toshiyuki Ishiwata
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Cancer Cells ◽  
Fibroblast Growth Factor ◽  
Therapeutic Target ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Colorectal Cancer Cells

Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: A potential therapeutic target in colorectal cancer

2011 ◽  
Vol 309 (2) ◽  
pp. 209-219 ◽  
Author(s):  
Yoko Matsuda ◽  
Toshiyuki Ishiwata ◽  
Kazuya Yamahatsu ◽  
Kiyoko Kawahara ◽  
Masahito Hagio ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Therapeutic Target ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Invasive Front ◽  
Potential Therapeutic Target

scholarly journals Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

2013 ◽  
Vol 12 (7) ◽  
pp. 1245-1254 ◽  
Author(s):  
Kilian M. Gust ◽  
David J. McConkey ◽  
Shannon Awrey ◽  
Paul K. Hegarty ◽  
Jing Qing ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Therapeutic Target ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth

Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer

Head & Neck ◽  
2014 ◽  
pp. n/a-n/a ◽  
Author(s):  
Andreas Schröck ◽  
Friederike Göke ◽  
Patrick Wagner ◽  
Maike Bode ◽  
Alina Franzen ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Therapeutic Target ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Potential Therapeutic Target ◽  
Sinonasal Cancer

Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer

2007 ◽  
Vol 98 (12) ◽  
pp. 1902-1913 ◽  
Author(s):  
Yuria Mano ◽  
Koji Takahashi ◽  
Nobuhisa Ishikawa ◽  
Atsushi Takano ◽  
Wataru Yasui ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Therapeutic Target ◽  
Fibroblast Growth Factor Receptor ◽  
Prognostic Biomarker ◽  
Growth Factor Receptor ◽  
Fibroblast Growth
Sign in / Sign up

Export Citation Format

Share Document